BC has traditionally been classified based on clinic-pathological features such as tumor size, stage, and nodal involvement, leading to the identification of multiple BC molecular subtypes based on hormone receptors (estrogen—ER and progesterone—PR) and HER2 status [4,5]. This evidence concerns the gene ERBB2 and breast cancer.